文献速递脑血管病认知障碍与痴呆

西洛他唑用于卒中二级预防与认知下降:系统综述与荟萃分析

Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis.
PubMed 文献 · Stroke · 2020-07-10

西洛他唑降低复发性缺血性卒中、出血性卒中、死亡及系统性出血,但增加头痛和心悸;长期使用获益更明显且不增加出血。多数试验来自亚太地区,认知和功能结局数据不足。

要点

  • 西洛他唑降低复发性缺血性卒中(OR=0.68)和出血性卒中(OR=0.43)。
  • 西洛他唑降低死亡(OR=0.64)和系统性出血(OR=0.73),但增加头痛和心悸。
  • 长期(>6个月)使用获益更明显,且不增加出血风险。

核心结论

  • 西洛他唑似乎对长期卒中二级预防有效,且不增加出血风险。
  • 多数试验针对亚太地区患者,需在西方国家开展更多试验评估认知下降、功能结局和耐受性。

研究设计与样本

  • 检索时间为2019年1月1日至2019年7月16日,计算Peto比值比(OR)和95%CI。

主要发现

  • 西洛他唑降低出血性卒中(16项试验,n=9736,OR=0.43 [95%CI 0.29-0.64];P=0.0001)。
  • 西洛他唑降低死亡(OR=0.64 [95%CI 0.49-0.83],P<0.0009)和系统性出血(n=8387,OR=0.73 [95%CI 0.54-0.99];P=0.04)。
  • 与安慰剂、阿司匹林或氯吡格雷相比,西洛他唑增加头痛和心悸。
  • 长期(>6个月)使用较短期使用更降低复发性缺血性卒中且不增加出血,在腔隙性卒中比例>40%的试验中更明显。

临床怎么用

  • 西洛他唑可考虑用于长期卒中二级预防,尤其腔隙性卒中比例较高的人群。
  • 使用中需注意头痛和心悸等不良反应。

局限性

  • 多数试验来自亚太地区,外推至其他人群需谨慎。
  • 数据不足以评估对认知、影像学、功能结局或耐受性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Cilostazol, a phosphodiesterase 3' inhibitor, is used in Asia-Pacific countries for stroke prevention, but rarely used elsewhere. In addition to weak antiplatelet effects, it stabilizes endothelium, aids myelin repair and astrocyte-neuron energy transfer in laboratory models, effects that may be beneficial in preventing small vessel disease progression. METHODS: A systematic review and meta-analysis of unconfounded randomized controlled trials of cilostazol to prevent stroke, cognitive decline, or radiological small vessel disease lesion progression. Two reviewers searched for papers (January 1, 2019 to July 16, 2019) and extracted data. We calculated Peto odds ratios (ORs) and 95% CIs for recurrent ischemic, hemorrhagic stroke, death, adverse symptoms, with sensitivity analyses. The review is registered (CRD42018084742). RESULTS: We included 20 randomized controlled trials (n=10 505), 18 in ischemic stroke (total n=10 449) and 2 in cognitive impairment (n=56); most were performed in Asia-Pacific countries. Cilostazol decreased recurrent ischemic stroke (17 trials, n=10 225, OR=0.68 [95% CI, 0.57-0.81]; P<0.0001), hemorrhagic stroke (16 trials, n=9736, OR=0.43 [95% CI, 0.29-0.64]; P=0.0001), deaths (OR=0.64 [95% CI, 0.49-0.83], P<0.0009), systemic bleeding (n=8387, OR=0.73 [95% CI, 0.54-0.99]; P=0.04), but increased headache and palpitations, compared with placebo, aspirin, or clopidogrel. Cilostazol reduced recurrent ischemic stroke more when given long (>6 months) versus short term without increasing hemorrhage, and in trials with larger proportions (>40%) of lacunar stroke. Data were insufficient to assess effects on cognition, imaging, functional outcomes, or tolerance. CONCLUSIONS: Cilostazol appears effective for long-term secondary stroke prevention without increasing hemorrhage risk. However, most trials related to Asia-Pacific patients and more trials in Western countries should assess its effects on cognitive decline, functional outcome, and tolerance, particularly in lacunar stroke and other presentations of small vessel disease.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. McHutchison C, Blair GW, Appleton JP, et al. Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis. Stroke. 2020. PMID: 32646330. doi:10.1161/STROKEAHA.120.029454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。